9 Meters Biopharma Inc
Change company Symbol lookup
Select an option...
NMTR 9 Meters Biopharma Inc
TJX TJX Companies Inc
OGE OGE Energy Corp
O Realty Income Corp
DMO Western Asset Mortgage Opportunity Fund Inc
TEX Terex Corp
JEPI JPMorgan Equity Premium Income ETF
SPYD SPDR® Portfolio S&P 500 High Dividend ETF
AAPL Apple Inc
VYM Vanguard High Dividend Yield Index Fund ETF Shares
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

Closing Price
$2.33
Day's Change
0.17 (7.87%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.34
Day's Low
2.10
Volume
(Heavy Day)
Volume:
119,836

10-day average volume:
70,107
119,836

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.